is prr going to close the gap at 12?, page-16

Thanks for your contribution arp33. If what you're saying is true, it is indeed very kind of you to share that with us.

Now, I was under the impression that one of the key selling points for PRR was that it faced little/no problems in the intellectual property department? Aren't CVac and Provenge two entirely different drugs develeoped by different groups of people? Or can everything topple over when DNDN turns around and says "hey, you stole the immunotherapy idea from us!"

I'm heavy and long PRR, but I for one would like to have a healthy/intellectual discussion rather than shoot down those who present negative information (which is unfortunately what happens 99% of the time on HC)